Synthesis of amino-modified magnetite nanoparticles coated with Hepama-1 and radiolabeled with 188Re for bio-magnetically targeted radiotherapy

Liang, Sheng; Wang, Yongxian; Zhang, Chunfu; Liu, Xiuqing

doi:10.1007/s10967-006-0223-5

Cited by 21 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24,25 Other promising, silica-based materials for combined FI and MRI, [26][27][28][29] combined FI and computed tomography (CT), 30 MRI and CT, 31 and even FI, MRI, and CT 32 have been reported but have not yet shown their applicability in vitro or in vivo. Moreover, combined diagnostics and therapeutics (theranostics) using silica nanoparticles has been accomplished 33 and demonstrated to be effective in vitro. [34][35][36] In addition to the size and composition, the shape and surface properties of silica can be well controlled.…”

mentioning

confidence: 99%

Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation

et al. 2008

View full text Add to dashboard Cite

Silica is a promising carrier material for nanoparticle-facilitated drug delivery, gene therapy, and molecular imaging. Understanding of their pharmacokinetics is important to resolve bioapplicability issues. Here we report an extensive study on bare and lipid-coated silica nanoparticles in mice. Results obtained by use of a wide variety of techniques (fluorescence imaging, inductively coupled plasma mass spectrometry, magnetic resonance imaging, confocal laser scanning microscopy, and transmission electron microscopy) showed that the lipid coating, which enables straightforward functionalization and introduction of multiple properties, increases bioapplicability and improves pharmacokinetics.

show abstract

mentioning

confidence: 99%

Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Silica-coated magnetite and SPIOs were functionalized with an antibody targeting human hepatocarcinoma cells and directly labeled with 188 Re-perrhenate after reduction of the protein disulfide bridges to sulfhydryl groups [101,102]. With this approach, the radiometal incorporation was efficient but approximately 25% of the NP-bound radioactivity was released in vitro in 24 hours.…”

Section: Technetium and Rhenium Radiolabelingmentioning

confidence: 99%

Radiolabeled Nanoplatforms: Imaging Hot Bullets Hitting their Target

Rossin

2011

Nanoplatform‐Based Molecular Imaging

View full text Add to dashboard Cite

Nanomedicine is a rapidly evolving field. Every year, new and more sophisticated nanoplatforms (NPs) designed to deliver drugs to specific targets or for molecular imaging of disease states make their appearance on the scientific scene. The assessment of the in vivo distribution of these NPs is the first step in order to fully understand their potential as candidate nanomedicines and to predict and prevent toxic side effects. To this aim, the incorporation of a radionuclide in the NP is of great advantage, as radiometric assays are rapid and quantitative. Furthermore, noninvasive nuclear imaging techniques are highly sensitive, achieve high tissue penetration and good spatial resolution, and can accelerate the translation of new NPs into the clinic. This chapter gives an overview of the strategies to label NPs with a variety of radionuclides (radiometals and radiohalogens), focusing on some of the hurdles that scientists must overcome (or take into consideration) when administering these radioconjugates in vivo. Furthermore, the latest achievements in molecular imaging of angiogenesis with radiolabeled NPs are reviewed.The most recent publications on nanoplatforms labeled with ␥ -and ␤ + -emitting radionuclides for SPECT and PET imaging are reviewed. Different strategies to label nanoplatforms are described, particularly those involving radiometals ( 64 Cu, 111 In, 67/68 Ga, 86 Y, 99m Tc, and 186/188 Re) and radiohalogens ( 123/124/125/131 I, 76 B, and 18 F). Some of the problems occurring when evaluating radiolabeled nanoplatforms in vivo are also covered. Finally, the use of radiolabeled nanoplatforms for angiogenesis imaging with PET and SPECT is discussed.

show abstract

“…Liang et al [148] successfully developed magnetic nanoparticles with glutaraldehyde crosslinker to link humanized MAb (Hepama-1) against liver cancer to prepare RINPs. These 20-nm magnetite NPs were coated with a fine layer of silane on the surface of the magnetite core and labeled with 188 Re.…”

Section: Radioimmunonanoparticles For Hyperthermiamentioning

confidence: 99%

Radioimmunonanoparticles for Cancer Imaging and Therapy

Natarajan

2011

Nanoplatform‐Based Molecular Imaging

View full text Add to dashboard Cite

Synthesis of amino-modified magnetite nanoparticles coated with Hepama-1 and radiolabeled with 188Re for bio-magnetically targeted radiotherapy

Cited by 21 publications

References 0 publications

Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation

Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation

Radiolabeled Nanoplatforms: Imaging Hot Bullets Hitting their Target

Radioimmunonanoparticles for Cancer Imaging and Therapy

Contact Info

Product

Resources

About